ImmunityBio (IBRX) News Today $2.74 -0.11 (-3.86%) Closing price 04:00 PM EasternExtended Trading$2.74 +0.00 (+0.18%) As of 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Is ImmunityBio, Inc. (NASDAQ:IBRX) The Top Penny Stock That Will Skyrocket?March 25 at 6:41 PM | msn.comClearwater Capital Advisors LLC Acquires 363,870 Shares of ImmunityBio, Inc. (NASDAQ:IBRX)Clearwater Capital Advisors LLC grew its holdings in ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 75.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 846,419 shares of the company's stock after acquiring an additMarch 18, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Earns "Buy" Rating from HC WainwrightMarch 16, 2025 | americanbankingnews.comImmunityBio (IBRX) Expected to Announce Earnings on TuesdayImmunityBio (NASDAQ:IBRX) will be releasing earnings before the market opens on Tuesday, March 18, Financial Modeling Prep reports.March 16, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Down 2.9% - What's Next?ImmunityBio (NASDAQ:IBRX) Trading Down 2.9% - Here's WhyMarch 15, 2025 | marketbeat.comHC Wainwright Reaffirms Buy Rating for ImmunityBio (NASDAQ:IBRX)HC Wainwright reaffirmed a "buy" rating and issued a $8.00 price objective on shares of ImmunityBio in a research note on Thursday.March 14, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Stock Price Up 4.4% - Should You Buy?ImmunityBio (NASDAQ:IBRX) Trading Up 4.4% - Should You Buy?March 14, 2025 | marketbeat.comImmunityBio's (IBRX) Buy Rating Reaffirmed at D. Boral CapitalD. Boral Capital reissued a "buy" rating and set a $30.00 price target on shares of ImmunityBio in a research report on Thursday.March 14, 2025 | marketbeat.comImmunityBio announces 1st dosing of rBCG in U.S. and 60 sites pendingMarch 13, 2025 | markets.businessinsider.comImmunityBio, Inc. (IBRX): Among the Stocks Under $10 With High Upside PotentialMarch 12, 2025 | insidermonkey.comQ1 Earnings Forecast for ImmunityBio Issued By HC WainwrightImmunityBio, Inc. (NASDAQ:IBRX - Free Report) - Equities researchers at HC Wainwright issued their Q1 2025 earnings estimates for shares of ImmunityBio in a research report issued to clients and investors on Thursday, March 6th. HC Wainwright analyst A. Maldonado forecasts that the company will pMarch 11, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Coverage Initiated by Analysts at HC WainwrightHC Wainwright started coverage on ImmunityBio in a report on Thursday. They issued a "buy" rating and a $8.00 price objective for the company.March 7, 2025 | marketbeat.comImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial MomentumMarch 7, 2025 | seekingalpha.comImmunityBio initiated with a Buy at H.C. WainwrightMarch 6, 2025 | markets.businessinsider.comImmunityBio (NASDAQ:IBRX) Trading Up 6.8% on Strong EarningsImmunityBio (NASDAQ:IBRX) Trading Up 6.8% After Earnings BeatMarch 5, 2025 | marketbeat.comWhy ImmunityBio Inc. (IBRX) Crashed on MondayMarch 4, 2025 | msn.comImmunityBio stock rises on Q4 earnings beat, revenue growthMarch 4, 2025 | investing.comImmunityBio (NASDAQ:IBRX) Shares Gap Down - Should You Sell?ImmunityBio (NASDAQ:IBRX) Shares Gap Down - Time to Sell?March 3, 2025 | marketbeat.comImmunityBio reports Q4 EPS (9c), consensus (13c)March 3, 2025 | markets.businessinsider.comImmunityBio: Q4 Earnings SnapshotMarch 3, 2025 | finance.yahoo.comImmunityBio (NASDAQ:IBRX) Announces Earnings Results, Beats Estimates By $0.11 EPSImmunityBio (NASDAQ:IBRX - Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.11.March 3, 2025 | marketbeat.comImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024March 3, 2025 | businesswire.comImmunityBio (NASDAQ:IBRX) Shares Gap Up - Should You Buy?ImmunityBio (NASDAQ:IBRX) Shares Gap Up - Here's WhyMarch 1, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Given "Buy" Rating at D. Boral CapitalD. Boral Capital reaffirmed a "buy" rating and issued a $30.00 price target on shares of ImmunityBio in a report on Friday.March 1, 2025 | marketbeat.comImmunityBio Shares Up, FDA Gives RMAT Designation for Treatment of Lymphopenia in Cancer PatientsFebruary 28, 2025 | marketwatch.comImmunityBio stock climbs 10% on FDA RMAT designationFebruary 28, 2025 | msn.comImmunityBio receives FDA RMAT designation for AnktivaFebruary 28, 2025 | markets.businessinsider.comImmunityBio receives FDA RMAT designation for AnktivaFebruary 28, 2025 | markets.businessinsider.comIMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating ImmunityBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmFebruary 27, 2025 | globenewswire.comImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic CancerFebruary 27, 2025 | businesswire.comImmunityBio (NASDAQ:IBRX) Trading Down 8.1% - Time to Sell?ImmunityBio (NASDAQ:IBRX) Trading Down 8.1% - Here's WhyFebruary 21, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Sees Unusually-High Trading Volume - Time to Buy?ImmunityBio (NASDAQ:IBRX) Sees Strong Trading Volume - Here's What HappenedFebruary 20, 2025 | marketbeat.comWhy ImmunityBio (IBRX) Is Surging TodayFebruary 20, 2025 | msn.comWhy ImmunityBio, Inc. (IBRX) Went Up On Wednesday?February 20, 2025 | msn.comFDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG ShortageFebruary 19, 2025 | finance.yahoo.comFDA authorizes ImmunityBio to provide rBCG to urologists amid shortagesFebruary 19, 2025 | markets.businessinsider.comImmunityBio (NASDAQ:IBRX) Trading Up 12.6% - Still a Buy?ImmunityBio (NASDAQ:IBRX) Trading 12.6% Higher - Should You Buy?February 15, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Receives Buy Rating from D. Boral CapitalD. Boral Capital reaffirmed a "buy" rating and set a $30.00 price target on shares of ImmunityBio in a research report on Friday.February 15, 2025 | marketbeat.comImmunityBio announces UK acceptance of Anktiva marketing applicationFebruary 13, 2025 | markets.businessinsider.comImmunityBio announces executive compensation updatesFebruary 13, 2025 | msn.comImmunityBio (NASDAQ:IBRX) Trading Down 6.8% - Here's WhyImmunityBio (NASDAQ:IBRX) Shares Down 6.8% - Time to Sell?February 5, 2025 | marketbeat.comImmunityBio, Inc. (NASDAQ:IBRX) Sees Large Growth in Short InterestImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) saw a large increase in short interest in January. As of January 15th, there was short interest totalling 50,010,000 shares, an increase of 12.6% from the December 31st total of 44,410,000 shares. Based on an average daily volume of 6,580,000 shares, the short-interest ratio is currently 7.6 days.February 3, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Down 6.8% - Here's What HappenedImmunityBio (NASDAQ:IBRX) Stock Price Down 6.8% - What's Next?February 3, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Stock Price Up 17.2% - Time to Buy?ImmunityBio (NASDAQ:IBRX) Trading 17.2% Higher - Should You Buy?January 31, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Trading Up 17.2% - Still a Buy?ImmunityBio (NASDAQ:IBRX) Stock Price Up 17.2% - Here's WhyJanuary 29, 2025 | marketbeat.comImmunityBio Shares Rise After Collaboration, Supply Agreement With BeiGeneJanuary 29, 2025 | marketwatch.comImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung CancerJanuary 29, 2025 | businesswire.comImmunityBio announces Anktiva MAA accepted for review by EMAJanuary 28, 2025 | markets.businessinsider.comD. Boral Capital Reaffirms "Buy" Rating for ImmunityBio (NASDAQ:IBRX)D. Boral Capital reaffirmed a "buy" rating and issued a $30.00 price target on shares of ImmunityBio in a report on Monday.January 28, 2025 | marketbeat.comD. Boral Capital Reiterates Buy Rating for ImmunityBio (NASDAQ:IBRX)D. Boral Capital reissued a "buy" rating and issued a $30.00 price objective on shares of ImmunityBio in a report on Monday.January 27, 2025 | marketbeat.com Remove Ads Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address IBRX Media Mentions By Week IBRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IBRX News Sentiment▼1.670.62▲Average Medical News Sentiment IBRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IBRX Articles This Week▼13▲IBRX Articles Average Week Remove Ads Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies QGEN News ROIV News SRPT News RVMD News BBIO News LNTH News LEGN News TGTX News AXSM News TLX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IBRX) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunityBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunityBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
